Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results through 48 Weeks from Two Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Certolizumab pegol is an Fc-Free, PEGylated anti-tumor necrosis factor biologic. In these phase 3 psoriasis studies, certolizumab pegol 200 mg and 400 mg every 2 weeks demonstrated statistically significant and clinically meaningful improvements versus placebo; no new safety signals were observed. Certolizumab pegol affords additional psoriasis treatment options.